ACACA and metabolic dysfunction-associated steatohepatitis: Gemcabene 100 mg/kg and telmisartan-treated mice, down-regulated ACC-1 mRNA expression levels compared to the vehicle-treated NASH mice (0.7 ± 0.1 compared to 0.9 ± 0.2), but had no effect on ACC-2.